araag2/HINT huggingface dataset:
Clinical trial NCT00062387 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: perifosine
SMILES: CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
Reason stopped: 
    administratively complete.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed squamous cell cancer of the head and neck

               -  Metastatic or recurrent disease

               -  Not amenable to surgery or radiotherapy

          -  Unidimensionally measurable disease

               -  At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by
                  CT scan

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2 OR

          -  Karnofsky 60-100%

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin normal

          -  AST/ALT no greater than 2.5 times upper limit of normal

        Renal

          -  Creatinine normal OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biological composition to perifosine

          -  No ongoing or active infection

          -  No other concurrent uncontrolled illness

          -  No psychiatric illness or social situation that would limit compliance with study
             requirements

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No more than 1 prior biologic/targeted regimen for recurrent or metastatic disease

        Chemotherapy

          -  No more than 1 prior adjuvant or neoadjuvant chemotherapy and/or concurrent
             chemoradiotherapy regimen

          -  No more than 1 prior chemotherapy regimen for recurrent or metastatic disease

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

        Radiotherapy

          -  At least 4 weeks since prior radiotherapy

        Other

          -  Recovered from prior therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents

          -  No other concurrent anticancer agents or therapies
Clinical trial NCT01136174 (phase 2, status: completed)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: placebo, bibf 1120, bibf 1120, bibf 1120
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of idiopathic pulmonary fibrosis (IPF) according to American Thoracic
             Society (ATS) /European Respiratory Society (ERS) guideline

          2. Forced vital capacity (FVC) 50-90%

          3. Diffusing capacity for carbon monoxide (DLCO) 30-79%

          4. For patients on pirfenidone, have been on a steady dose for at least 3 months

        Exclusion criteria:

          1. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 1.5 x upper limit
             of normal range (ULN) at screening.

          2. Bilirubin > 1.5 x ULN at screening.

          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC <0.7) at screening.

          4. Continuous oxygen supplementation.

          5. Active infection at screening or randomisation.

          6. Being treated with any of the following concomitant medications.

               -  Oral corticosteroid medication at unstable dose

               -  ketoconazole or atazanavir

          7. Patients who are expected to go on to lung transplantation, have rapidly deteriorating
             disease, or have a life expectancy less than 3 months from screening
Clinical trial NCT00524667 (phase 2, status: terminated)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: valproic acid & fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    terminated due to poor accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Active CLL (as defined by the National Cancer Institute Working Group)

          -  Patients must have received at least one prior therapy for CLL and have been treated
             with a nucleoside analogue.

          -  Recruitment will be limited to those with an ECOG performance status of 2 or less.

        Exclusion Criteria:

          -  Patients who are pregnant or breastfeeding

          -  Patients with a history of autoimmune cytopenias

          -  Patients with platelets < 50 x 109/L or an absolute neutrophil count < 1.5X109/L

          -  Patients with hepatic disease or an AST/ALT 6x above the upper limit of normal

          -  Patients with a calculated creatinine clearance < 30 ml/min using the Cockroft and
             Gault formula

          -  Patients with a history of pancreatitis

          -  Patients who are receiving drugs that affect VPA protein binding or metabolism

          -  Patients with active infection, HIV or active viral hepatitis

          -  Patients with active secondary malignancy or who have central nervous system
             involvement with CLL

          -  Patients diagnosed with more an aggressive lymphoproliferative disorder such as
             Richter's transformation
Clinical trial NCT00284258 (phase 2/phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cpt-11 and ts-1, cpt-11, 5-fu and l-lv
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed colorectal cancer

          -  Locally advanced and/or metastatic colorectal cancer

          -  Have prior chemotherapy as first line treatment

          -  No prior irinotecan administration

          -  Able to take oral medication

          -  Age 20 to 75

          -  Performance status 0 or 1 (ECOG)

          -  WBC 3,000-12,000 / mm^3

          -  Platelet ≥100,000 / mm^3

          -  AST and ALT ≤ 100 IU/L

          -  Creatinine ≤ 1.2 mg/dL

          -  Bilirubin ≤ 1.5 mg/dL

        Exclusion Criteria:

          -  Prior radio therapy for colorectal cancer

          -  Other malignancies in the past 5 years

          -  Serious illness or medical condition
Clinical trial NCT00318214 (phase 2, status: terminated)
Conditions: foot ulcer, diabetic, diabetes complications
ICD codes: E10.9, E11.9, E13.9, E10.8, E11.8, E13.8, E08.9
Drugs: mre0094, vehicle gel
SMILES: NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC(OCCC2=CC=C(Cl)C=C2)=N1, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    the study had poor enrollment with only 16 patients randomized across 19 study centers over an
    18-month period.
  
Eligibility criteria:

        Inclusion Criteria:

        Participants included in the study must:

          -  Have type 1 or type 2 diabetes mellitus.

          -  Have problems with the nerves in their feet.

          -  Have a large ulcer or multiple ulcers on the bottom surface of their foot that has
             been present for 3 weeks or more and is of sufficient size to qualify for the study.

          -  Be able to apply study drug to their ulcer, or have a caregiver do it.

          -  Be able to visit the doctor regularly during the 4½ month study.

        Exclusion Criteria:

        Participants may not participate in the study if:

          -  Their ulcer is caused by bad blood flow to their foot.

          -  Their ulcer is infected.

          -  They cannot wear an off-loading device during the study to take pressure off the
             ulcer.

          -  They have certain other diseases, or are using certain types of drugs.
Clinical trial NCT00545129 (phase 2, status: completed)
Conditions: neoplasm metastasis, palliative care
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, Z51.5
Drugs: tanezumab 10 mg iv, iv placebo for tanezumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has
             spread to bone, causing moderate to severe bone pain.

          -  Requires daily opioid medication

        Exclusion Criteria:

          -  Patients who do not have bone pain caused by cancer are not eligible for the study.

          -  Patients who started chemotherapy less than 4 weeks ago, or who completed radiotherapy
             less than 4 weeks ago, are not eligible.

          -  Known history or evidence of osteoarthritis. History of significant trauma to a major
             joint within 1 year prior to Screening.

          -  Known history of rheumatoid arthritis.
Clinical trial NCT00487942 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: armodafinil, armodafinil, armodafinil, placebo
SMILES: NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1, NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1, NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  The patient has a diagnosis of schizophrenia according to the DSM-IV-TR criteria as
             determined by the SCID and has been clinically stable in a nonacute phase of their
             illness for at least 8 weeks prior to the baseline visit.

          -  The patient has received treatment with olanzapine, oral risperidone, or paliperidone
             for schizophrenia for at least 6 weeks prior to the screening visit and has been on a
             stable dose of olanzapine, oral risperidone, or paliperidone for at least 4 weeks
             prior to the screening visit. The patient is prepared to remain at these stable
             dosages for the duration of the study.

          -  The patient is a man or woman 18 through 60 years of age.

          -  The patient is in good health (except for the diagnosis of schizophrenia) as judged by
             the investigator on the basis of medical and psychiatric history, medical examination,
             ECG, serum chemistry, hematology, and urinalysis.

          -  Women of childbearing potential must use a medically accepted method of contraception
             and must agree to continue use of this method for the duration of the study and for 30
             days after participation in the study.

          -  The patient must be willing and able to comply with study restrictions, to remain at
             the clinic for the required duration during the study period, and to return to the
             clinic for the follow-up evaluation as specified in this protocol.

        Key Exclusion Criteria:

          -  The patient has any Axis I disorder, including schizoaffective disorder and sleep
             disorders, apart from schizophrenia, and nicotine dependence.

          -  The patient has tardive dyskinesia or any other clinically significant movement
             disorder.

          -  The patient has any clinically significant uncontrolled medical (including illnesses
             related to the cardiovascular, renal, or hepatic systems) or surgical condition.

          -  The patient has previously received modafinil or armodafinil, or the patient has a
             known sensitivity to any ingredients in the study drug tablets.

          -  The patient is a pregnant or lactating woman. (Any woman becoming pregnant during the
             study will be withdrawn from the study.)
Clinical trial NCT00572585 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: aeb071, placebo
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18-75 years males and females

          -  Female subjects of childbearing potential must be using two methods of contraception

          -  Active, moderate to severe disease

          -  Poor response to or no toleration of conventional therapy (e.g. steroids, mesalamine)

          -  Good communication with the investigator, understanding and compliance with the
             requirements of the study and written informed consent

        Exclusion Criteria:

          -  Allergy to the drug

          -  Very low or high body weight

          -  Ongoing treatment with specific other medication (e.g. antibiotics)

          -  Diagnosis of primary sclerosing cholangitis

          -  Renal impairment

          -  Toxic megacolon

          -  Presence or history of specific other diseases, cancer, cardiac abnormalities,
             abnormal laboratory findings

          -  History of alcohol or drug abuse

          -  Pregnant or breastfeeding women

          -  Positive HIV, Hepatitis B or Hepatitis C test result

        Other protocol-defined inclusion/exclusion criteria do apply
Clinical trial NCT00238303 (phase 2, status: completed)
Conditions: adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor
ICD codes: G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: vorinostat
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed grade 4 astrocytoma (glioblastoma multiforme), including
             gliosarcoma, at primary diagnosis or recurrence

               -  Progressive or recurrent disease

          -  Measurable or evaluable disease by MRI or CT scan

          -  Performance status - ECOG 0-2

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 8 g/dL

          -  AST ≤ 3 times upper limit of normal (ULN)

          -  Bilirubin normal

          -  Creatinine ≤ 1.5 times ULN

          -  No myocardial infarction within the past 6 months

          -  No congestive heart failure

          -  No life-threatening ventricular arrhythmia requiring ongoing maintenance therapy

          -  No known HIV positivity

          -  Not immunocompromised except if related to the use of corticosteroids

          -  No known hypersensitivity to any of the components of the study drug

          -  No uncontrolled infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No other malignancy

          -  No other severe disease that would preclude study participation

          -  Prior adjuvant chemotherapy allowed

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

          -  More than 2 weeks since prior small molecule cell cycle inhibitor

          -  Concurrent corticosteroids allowed as long as dose has been stable for ≥ 1 week

          -  At least 8 weeks since prior radiotherapy

               -  Must have evidence of tumor progression by MRI or CT scan after radiotherapy

          -  More than 6 weeks since prior stereotactic radiosurgery or interstitial brachytherapy,
             unless 1 of the following criteria is met:

               -  There is a separate lesion by MRI outside of the prior treatment field

               -  There is evidence of recurrent disease by biopsy, MRI spectroscopy, or
                  positron-emission tomography scan

          -  More than 2 weeks since prior valproic acid
Clinical trial NCT00151775 (phase 2/phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: olmesartan medoxomil, placebo, olmesartan medoxomil
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient's seated systolic BP (SeSBP) will be greater than or equal to 95th
             percentile for gender and height-for- age, or greater than or equal to 90th percentile
             if the patient is diabetic, or has glomerular kidney disease, or has a family history
             of hypertension.

          -  Negative for hepatitis B and C

          -  Negative for HIV

        Exclusion Criteria:

          -  Patient should not have serious other conditions that could interfere with the
             analysis of the results or that could interfere with the well-being of the patient in
             the trial.

          -  Known sensitivity to olmesartan medoxomil

          -  Taking prohibited medication

          -  Consumed greater than 180 mg of caffeine daily

          -  Malignant hypertension

          -  History of congestive heart failure, cardiomyopathy, or obstructive valve disease

          -  Renal transplant within the previous 6 months

          -  Severe nephritic syndrome not in remission
Clinical trial NCT00006371 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: aminoglutethimide, ketoconazole, therapeutic hydrocortisone
SMILES: CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the prostate Stage IV
        (D0.5; no evidence of disease on CT or bone scan after testicular androgen ablation) PSA
        progression after testicular androgen ablation with or without antiandrogen therapy
        Progression is defined as at least 2 consecutive rising PSA levels (drawn at least 2 weeks
        apart) with a greater than 50% rise above the last nadir level (arbitrary PSA at least 2
        ng/dL)

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
        Other: No other medical conditions that would increase risk Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: See Disease Characteristics Greater than 4 weeks since prior flutamide
        (6 weeks for bicalutamide or nilutamide) No prior aminoglutethimide or ketoconazole for
        prostate cancer Continuation of primary testicular androgen suppression (i.e., LHRH analog)
        required Radiotherapy: Not specified Surgery: Not specified Other: No concurrent
        terfenadine, astemizole, cisapride, or other medicines known to interact with ketoconazole
Clinical trial NCT00667953 (phase 1/phase 2, status: terminated)
Conditions: melanoma, advanced melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: gleevec + temozolomide
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Reason stopped: 
    difficulty enrolling subjects
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed melanoma that is metastatic or unresectable and for which
             standard curative or palliative measures do not exist or are no longer effective

          -  Prior chemotherapy, immunotherapy, radiation therapy (Phase I portion only), cytokine,
             biologic, or vaccine therapy is permitted, however no prior treatment with
             temozolomide

          -  Measurable disease

          -  ECOG performance status <= 2

          -  Life expectancy greater than 3 months

        Exclusion Criteria:

          -  No prior treatment with temozolomide or imatinib mesylate

          -  Organ allografts

          -  Prior radiotherapy, or prior intratumor injection therapy, to areas of measurable
             disease that are used as target indicator lesions, unless progression has occurred at
             that site or measurable disease has developed outside the treatment area

          -  Pregnancy or lactation

          -  History of second cancer

          -  Known hypersensitivity to temozolomide or imatinib

          -  Use of any experimental therapy within 3 weeks prior to baseline evaluations done
             prior to enrollment
Clinical trial NCT00183794 (phase 2, status: completed)
Conditions: ovarian carcinoma, peritoneal neoplasms
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: docetaxel and gemcitabine
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven diagnosis of epithelial ovarian ca

          -  Must have platinum-resistant disease. (Defined as progression during the most recent
             platinum-based chemotx or relapse < 6 months after the most recent platinum-based
             chemotx regimen.)

          -  Measurable or evaluable disease. (Patients whose dz is manifested only as an elevated
             CA-125 [greater than or equal to 100] are eligible. If an elevated CA-125 is the only
             manifestation of dz, it must be confirmed on 2 separate times, at least 2 weeks apart.
             Patients with positive cytology only are not eligible.)

          -  Greater than or equal to 18 years of age

          -  GOG performance status less than or equal to 2

          -  AGC/ANC greater than or equal to 1.5; platelets greater than or equal to 100,000;
             hemoglobin (Hgb) greater than or equal to 8.0.

          -  Creatinine less than or equal to 2.0

          -  Total bilirubin less than or equal to upper limit of normal (uln)

          -  SGOT and/or SGPT less than or equal to 2.5 x uln if alkaline phosphatase less than or
             equal to uln, or alkaline phosphatase less than or equal to 4 x uln if transaminases
             are less than or equal to uln. (If both SGOT/SGPT >1.5 x uln and alkaline phosphatase
             > 2.5 x uln, patient is not eligible.)

          -  Fully recovered from acute toxicities secondary to prior treatment (tx)

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior treatment with gemcitabine or docetaxel

          -  Underlying medical, psychiatric, or social conditions that would preclude patient from
             receiving treatment

          -  Peripheral neuropathy greater than or equal to Grade 2

          -  No prior tx with cisplatin or carboplatin